Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ZYNE
  • CUSIP:
Key Metrics:
  • Previous Close: $21.46
  • 50 Day Moving Average: $19.21
  • 200 Day Moving Average: $14.06
  • 52-Week Range: $5.17 - $23.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.69
  • P/E Growth: 0.00
  • Market Cap: $220.46M
  • Outstanding Shares: 9,953,000
  • Beta: 4.87
Profitability:
  • Return on Equity: -63.78%
  • Return on Assets: -56.66%
Debt:
  • Current Ratio: 7.19%
  • Quick Ratio: 7.19%
Additional Links:
Companies Related to Zynerba Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Zynerba Pharmaceuticals (NASDAQ:ZYNE) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.43 (41.79% upside)

Analysts' Ratings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Show:
DateFirmActionRatingPrice TargetDetails
1/5/2017Cantor FitzgeraldReiterated RatingOverweight$28.00View Rating Details
12/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$42.00View Rating Details
12/18/2016Oppenheimer Holdings, Inc.Set Price TargetBuy$29.00View Rating Details
12/16/2016HC WainwrightReiterated RatingBuy$22.00View Rating Details
12/6/2016Jefferies Group LLCReiterated RatingBuy -> Buy$32.00View Rating Details
9/7/2016Canaccord GenuityReiterated RatingBuy$35.00View Rating Details
9/6/2016Roth CapitalSet Price TargetBuy$25.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/14/2016Q3 2016($0.69)($0.67)ViewN/AView Earnings Details
8/11/2016Q2($0.53)($0.70)ViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.49)ViewN/AView Earnings Details
3/14/2016Q415($0.29)($0.62)ViewN/AView Earnings Details
11/11/2015Q3($0.41)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Current Year EPS Consensus Estimate: $-2.59 EPS
Next Year EPS Consensus Estimate: $-2.47 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.51)($0.43)($0.47)
Q2 20162($0.51)($0.48)($0.50)
Q3 20162($0.56)($0.54)($0.55)
Q4 20163($0.71)($0.63)($0.68)
Q1 20171($0.53)($0.53)($0.53)
Q2 20172($0.72)($0.53)($0.63)
Q3 20171($0.45)($0.45)($0.45)
Q4 20172($0.61)($0.44)($0.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Insider Ownership Percentage: 10.02%
Institutional Ownership Percentage: 15.00%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/29/2016Michael RappMajor ShareholderBuy10,000$15.85$158,500.00View SEC Filing  
12/7/2016James E FickenscherCFOBuy7,000$14.08$98,560.00View SEC Filing  
8/16/2016Suzanne M HanlonInsiderSell3,000$10.53$31,590.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
DateHeadline
benzinga.com logoCannabis Industry Expert Talks Cultivation Licenses In Canada And Maturation Of Capital Markets (NASDAQ:ZYNE)
www.benzinga.com - February 21 at 4:22 PM
finance.yahoo.com logoPatterson Companies (PDCO) Q3 Earnings: What's in Store? (NASDAQ:ZYNE)
finance.yahoo.com - February 21 at 4:22 PM
News IconEarnings According to Analysts for Zynerba Pharmaceuticals Inc ... - Aiken Advocate (NASDAQ:ZYNE)
aikenadvocate.com - February 21 at 8:01 AM
News IconDistorted Science: Does CBD Change to THC in the Stomach, and Who Benefits By Claiming It Does? (NASDAQ:ZYNE)
www.alternet.org - February 20 at 7:44 PM
News IconZynerba Pharmaceuticals Inc ZYNE Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:ZYNE)
www.bioportfolio.com - February 20 at 7:44 PM
finance.yahoo.com logoMedtronic (MDT) Q3 Earnings: Disappointment in the Cards? (NASDAQ:ZYNE)
finance.yahoo.com - February 20 at 8:00 AM
News IconZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) One of the More Legit Marijuana Companies (NASDAQ:ZYNE)
streetregister.com - February 18 at 7:46 PM
News IconThe Must-Know Technicals As They Stand For Zynerba Pharmaceuticals, Inc. (ZYNE) - NY Stock News (NASDAQ:ZYNE)
nystocknews.com - February 17 at 5:23 PM
News IconZynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) is Attracting Smart Money - Small Cap Exclusive (press release) (NASDAQ:ZYNE)
smallcapexclusive.com - February 17 at 5:23 PM
News IconAmericans' Favorable Outlook on the Cannabis Market (NASDAQ:ZYNE)
www.medindia.net - February 17 at 9:41 AM
News IconZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Sees The Needle Move on Volume - Winfield Review (NASDAQ:ZYNE)
winfieldreview.com - February 15 at 7:06 AM
News IconZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Charts Indicating Positive Momentum - Winfield Review (NASDAQ:ZYNE)
winfieldreview.com - February 15 at 7:06 AM
News IconImpact of Brokerage Rating on Zynerba Pharmaceuticals, Inc.(ZYNE) - Morning Outlook (NASDAQ:ZYNE)
www.morningoutlook.com - February 15 at 7:06 AM
globenewswire.com logoZynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewswire (press release) (NASDAQ:ZYNE)
globenewswire.com - February 10 at 6:51 AM
finance.yahoo.com logoZynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares (NASDAQ:ZYNE)
finance.yahoo.com - February 10 at 6:51 AM
biz.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ZYNE)
biz.yahoo.com - February 10 at 6:51 AM
finance.yahoo.com logoNativis Expands Board of Directors with Appointment of Dr. Daniel Kisner (NASDAQ:ZYNE)
finance.yahoo.com - February 7 at 4:20 PM
investopedia.com logoInnovative Marijuana-Based Drug on Horizon (ZYNE, INSY) (NASDAQ:ZYNE)
www.investopedia.com - February 7 at 4:20 PM
News IconFinancialBuzz.com: Legal Cannabis Market Gains Popularity (NASDAQ:ZYNE)
www.medindia.net - February 7 at 4:20 PM
investopedia.com logoInnovative Marijuana-Based Medicines In the Making (NASDAQ:ZYNE)
www.investopedia.com - February 7 at 4:20 PM
4-traders.com logoZynerba Pharmaceuticals : Spending on Legal Cannabis Accelerates (NASDAQ:ZYNE)
www.4-traders.com - February 4 at 7:34 AM
News IconInvestor Monitor: Narrowing in on Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - The Tribune (NASDAQ:ZYNE)
lakecitytribune.com - January 27 at 3:30 PM
benzinga.com logoMid-Day Market Update: Oclaro Surges Following Strong Q2 ... - Benzinga (NASDAQ:ZYNE)
www.benzinga.com - January 21 at 6:29 AM
News IconZynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Possible Bearish Divergence - Live Trading News (NASDAQ:ZYNE)
www.livetradingnews.com - January 21 at 6:29 AM
fool.com logoWhy Zynerba Pharmaceuticals Inc. Is Tanking Today - Motley Fool (NASDAQ:ZYNE)
www.fool.com - January 21 at 6:29 AM
bizjournals.com logoDeveloper of cannabinoid patch seeking $50M from stock sale (NASDAQ:ZYNE)
www.bizjournals.com - January 21 at 6:29 AM
streetinsider.com logoZynerba Pharma (ZYNE) Prices 2.8M Shares at $18 Per Share (NASDAQ:ZYNE)
www.streetinsider.com - January 20 at 7:23 AM
4-traders.com logoZYNERBA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) (NASDAQ:ZYNE)
www.4-traders.com - January 20 at 7:23 AM
rttnews.com logoZynerba Prices Offering At $18/Share (NASDAQ:ZYNE)
www.rttnews.com - January 20 at 7:23 AM
News IconZynerba Pharmaceuticals Inc (NASDAQ:ZYNE): We Bought The Stock At $14.65, So far Up A Whopping 55% In No Time (NASDAQ:ZYNE)
www.marketnewscall.com - January 20 at 7:23 AM
us.rd.yahoo.com logoZynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock (NASDAQ:ZYNE)
us.rd.yahoo.com - January 20 at 7:23 AM
biz.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an (NASDAQ:ZYNE)
biz.yahoo.com - January 20 at 7:23 AM
fool.com logoWhy Zynerba Pharmaceuticals Inc. Is Tanking Today (NASDAQ:ZYNE)
www.fool.com - January 19 at 12:33 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Wall Street Beacon (NASDAQ:ZYNE)
wsbeacon.com - January 19 at 8:15 AM
rttnews.com logoZynerba Pharmaceuticals Inc. (ZYNE) Is Falling After Offering Announcement - RTT News (NASDAQ:ZYNE)
www.rttnews.com - January 19 at 8:15 AM
finance.yahoo.com logoZynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock (NASDAQ:ZYNE)
finance.yahoo.com - January 19 at 8:15 AM
biz.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:ZYNE)
biz.yahoo.com - January 19 at 8:15 AM
News IconWill The Needle Move For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ZYNE)
wsbeacon.com - January 17 at 8:05 AM
investing.com logoZynerba Pharmaceuticals Inc (ZYNE) (NASDAQ:ZYNE)
www.investing.com - January 15 at 5:52 AM
finance.yahoo.com logoZynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 9.5% (NASDAQ:ZYNE)
finance.yahoo.com - January 12 at 8:18 AM
benzinga.com logoZynerba Could See 3 Clinical Study Catalysts In 2017's First Half (NASDAQ:ZYNE)
www.benzinga.com - January 5 at 7:46 AM
us.rd.yahoo.com logo7:04 am Zynerba Pharma initiates the FAB-C Phase 2 clinical trial of ZYN002 cannabidiol gel in children with Fragile X syndrome; co anticipates having top line results late in 1H17 (NASDAQ:ZYNE)
us.rd.yahoo.com - January 5 at 7:46 AM
biz.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:ZYNE)
us.rd.yahoo.com - January 5 at 7:46 AM
rttnews.com logoZynerba Pharmaceuticals Inc. (ZYNE) Rose To Over An 8-Month High - RTT News (NASDAQ:ZYNE)
www.rttnews.com - January 4 at 7:56 AM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Prospect Journal (NASDAQ:ZYNE)
prospectjournal.com - January 3 at 8:09 AM
streetinsider.com logoZynerba Pharma (ZYNE) Initiates FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 Cannabidiol - StreetInsider.com (NASDAQ:ZYNE)
www.streetinsider.com - January 3 at 8:09 AM
publicnow.com logoZynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome (NASDAQ:ZYNE)
www.publicnow.com - January 3 at 8:09 AM
nasdaq.com logoThe 10 Best Stocks to Buy for 2017: The Experts’ Picks (NASDAQ:ZYNE)
www.nasdaq.com - December 30 at 4:31 AM
News IconHome Business Zynerba Pharmaceuticals Inc. (ZYNE) stock starts with “Buy” rating in research note... - BNB Daily (blog) (NASDAQ:ZYNE)
www.baseball-news-blog.com - December 28 at 5:49 AM
News IconCan This Stock Gain Traction: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Prospect Journal (NASDAQ:ZYNE)
prospectjournal.com - December 27 at 8:01 AM

Social

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Where is Zynerba Pharmaceuticals' stock going? Where will Zynerba Pharmaceuticals' stock price be in 2017?

7 brokers have issued 12 month target prices for Zynerba Pharmaceuticals' stock. Their predictions range from $22.00 to $42.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $30.43 in the next year.

When will Zynerba Pharmaceuticals announce their earnings?

Zynerba Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

What are analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:

  • According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (2/18/2017)

  • Oppenheimer Holdings, Inc. analysts commented, "Zynerba reported 1Q16 results on Thursday, May 12th which were largely in-line. The company continues to track to near-term catalysts in the mid- and second half 2016 timeframes. We continue to believe that the relationship between GW Pharmaceuticals’ Epidiolex program and Zynerba’s ZYN002 program will be closely linked. GW already announced positive results from its cannabidiol program in Dravet Syndrome patients in mid-March, and has additional data read-outs in 2Q16 and 3Q16. Our understanding is that there may be some concern over cannabidiol’s role in enhancing the conversion of clobazam to norclobazam, an active metabolite. One important distinction in Zynerba’s trials from GW’s is that Zynerba is excluding clobazam as a concomitant medication." (5/16/2016)

Who owns Zynerba Pharmaceuticals stock?

Zynerba Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (8.46%), J. Goldman & Co LP (0.72%) and GSA Capital Partners LLP (0.14%). Company insiders that own Zynerba Pharmaceuticals stock include James E Fickenscher, Michael Rapp and Suzanne M Hanlon.

Who bought Zynerba Pharmaceuticals stock? Who is buying Zynerba Pharmaceuticals stock?

Zynerba Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, J. Goldman & Co LP and GSA Capital Partners LLP. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include James E Fickenscher and Michael Rapp.

How do I buy Zynerba Pharmaceuticals stock?

Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Zynerba Pharmaceuticals stock cost?

One share of Zynerba Pharmaceuticals stock can currently be purchased for approximately $21.46.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Earnings History Chart

Earnings by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Dividend History Chart

Dividend Payments by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Last Updated on 2/22/2017 by MarketBeat.com Staff